Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이경은 | * |
dc.date.accessioned | 2020-12-21T16:30:03Z | - |
dc.date.available | 2020-12-21T16:30:03Z | - |
dc.date.issued | 2020 | * |
dc.identifier.issn | 0171-5216 | * |
dc.identifier.issn | 1432-1335 | * |
dc.identifier.other | OAK-28341 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/255741 | - |
dc.description.abstract | Purpose Although immune-checkpoint inhibitors (ICIs) have emerged as therapeutic options for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC), concerns have been raised on exceptional acceleration of tumor growth during treatment with ICIs, a condition described as hyperprogressive disease (HPD). This study examined the incidence, potential predictors, and clinical impact of HPD in R/M-HNSCC. Methods We retrospectively collected data of patients with R/M-HNSCC treated with ICIs between January 2013 and June 2018 from 11 medical centers in Korea. HPD was defined as tumor growth kinetics ratio (TGKr) > 2, which was calculated by comparing TGK on ICIs with that before treatment with ICIs. Results Of 125 patients, 68 (54.4%) obtained progressive disease as their best responses (progressors). HPD was identified in 18 (26.5% of progressors, 14.4% of total) patients. Relatively younger age, primary tumor of oral cavity, and previous locoregional irradiation were significant predictors of HPD according to multivariable analysis (p = 0.040, 0.027, and 0.015, respectively). Compared to patients without HPD, patients with HPD had significantly shorter median progression-free survival (PFS) (1.2 vs. 3.4 months,p < 0.001) and overall survival (OS) (3.4 vs. 10.7 months,p = 0.047). However, interestingly, HPD did not significantly affect the therapeutic benefit of post-ICIs chemotherapy. Conclusions Younger patients with oral cavity cancer or prior treatment with locoregional radiotherapy could be regarded potential risk groups for HPD in patients with R/M-HNSCC treated with ICIs. Although HPD could consistently predict poorer survival outcomes, patients who experienced HPD with ICIs should not be excluded from the subsequent salvage chemotherapy treatments. | * |
dc.language | English | * |
dc.publisher | SPRINGER | * |
dc.subject | Hyperprogressive disease | * |
dc.subject | Immune-checkpoint inhibitors | * |
dc.subject | Prognostic | * |
dc.subject | Impact | * |
dc.subject | Recurrent and | * |
dc.subject | or metastatic | * |
dc.subject | Head and neck squamous carcinoma | * |
dc.title | Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12 | * |
dc.type | Article | * |
dc.relation.issue | 12 | * |
dc.relation.volume | 146 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 3359 | * |
dc.relation.lastpage | 3369 | * |
dc.relation.journaltitle | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | * |
dc.identifier.doi | 10.1007/s00432-020-03316-5 | * |
dc.identifier.wosid | WOS:000548812900001 | * |
dc.identifier.scopusid | 2-s2.0-85087895241 | * |
dc.author.google | Park, Jihyun | * |
dc.author.google | Chun, Sang Hoon | * |
dc.author.google | Lee, Yun-Gyoo | * |
dc.author.google | Chang, Hyun | * |
dc.author.google | Lee, Keun-Wook | * |
dc.author.google | Kim, Hye Ryun | * |
dc.author.google | Shin, Seong Hoon | * |
dc.author.google | An, Ho Jung | * |
dc.author.google | Lee, Kyoung Eun | * |
dc.author.google | Hwang, In Gyu | * |
dc.author.google | Ahn, Myung-Ju | * |
dc.author.google | Kim, Sung-Bae | * |
dc.author.google | Keam, Bhumsuk | * |
dc.contributor.scopusid | 이경은(7501517217;58364338700) | * |
dc.date.modifydate | 20240123091958 | * |